- Home
- FLNG vs XGN Comparison
FLNG vs XGN Comparison
Compare FLNG & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FLNG | XGN |
|---|---|---|
| Founded | 2006 | 2002 |
| Country | Bermuda | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 253.9M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | FLNG | XGN |
|---|---|---|
| Price | $24.79 | $6.69 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $23.00 | $13.67 |
| AVG Volume (30 Days) | ★ 431.5K | 246.3K |
| Earning Date | 02-03-2026 | 11-04-2025 |
| Dividend Yield | ★ 11.93% | N/A |
| EPS Growth | ★ 7.64 | N/A |
| EPS | ★ 1.82 | N/A |
| Revenue | ★ $351,034,000.00 | $63,599,000.00 |
| Revenue This Year | N/A | $22.15 |
| Revenue Next Year | $2.85 | $15.26 |
| P/E Ratio | $13.82 | ★ N/A |
| Revenue Growth | N/A | ★ 14.08 |
| 52 Week Low | $19.46 | $2.67 |
| 52 Week High | $27.67 | $12.23 |
Technical Indicators
Market Signals| Indicator | FLNG | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 39.94 | 30.79 |
| Support Level | $25.03 | $6.37 |
| Resistance Level | $25.60 | $7.29 |
| Average True Range (ATR) | 0.46 | 0.35 |
| MACD | -0.06 | 0.05 |
| Stochastic Oscillator | 8.39 | 30.82 |
Price Performance
Historical ComparisonAbout FLNG FLEX LNG Ltd.
Flex LNG Ltd is an LNG shipping company with a fleet of next-generation LNG carriers with large cargo capacity. The fleet consists of thirteen modern LNG ships, ten existing and three under construction for delivery. All LNG carriers are equipped with slow-speed, two-stroke engines MEGI or X-DF propulsion which will provide Charterers with tonnage offering advantages in form of reduced fuel consumption and lowered boil-off rates.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.